lysophosphatidic acid has been researched along with Cryptogenic Fibrosing Alveolitis in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 8 (47.06) | 2.80 |
| Authors | Studies |
|---|---|
| Charles, ED; Corte, TJ; Elpers, B; Fischer, A; Goldin, JG; Lancaster, L; Maher, TM; Minnich, A; Ogura, T; Palmer, SM; Smith, RA; Suda, T; Swigris, JJ; Tirucherai, GS; Watanabe, H; Xiao, H; Zhan, X | 1 |
| Aihara, M; Ali, H; Azuma, M; Has, RY; Kagawa, K; Kawano, H; Koyama, K; Morito, K; Nishioka, Y; Takahashi, N; Tanaka, T | 1 |
| Nakamura, Y; Shimizu, Y | 1 |
| Amari, G; Armani, E; Beato, C; Capelli, AM; Civelli, M; Delcanale, M; Di Lascia, MR; Giuliani, M; Iotti, N; Marchini, G; Mundi, C; Murarolli, F; Murgo, A; Pagano, M; Pappani, A; Puccini, P; Raveglia, LF; Remelli, R; Rizzi, A; Saccani, F; Tigli, L; Villetti, G | 1 |
| Jia, G; Li, Q; Liu, J; Neighbors, M; Sandoval, W; Tew, GW; Wong, WR; Zhu, SJ | 1 |
| Brindley, DN; Hemmings, DG | 1 |
| Valentine, WJ; Yanagida, K | 1 |
| Andreoli, M; Crystal, RG; Leopold, PL; Nathan, S; Zhang, H | 1 |
| Kokotos, G; Kokotou, MG; Limnios, D; Nikolaou, A; Psarra, A | 1 |
| Aidinis, V; Budd, DC; Kaffe, E; Müller, S; Ninou, I; Stevenson, CS; Ullmer, C | 1 |
| Allamasey, L; Blanqué, R; Desrivot, J; Diderichsen, PM; Fagard, L; Fieuw, A; Namour, F; Taneja, A; Van der Aar, E | 1 |
| Berdyshev, EV; Brenner, LN; Gorshkova, IA; Mathai, SK; Montesi, SB; Shea, BS; Tager, AM | 1 |
| Aubry, AF; Easter, J; Minnich, A; Onorato, JM; Shipkova, P; Tymiak, A | 1 |
| Cheng, J; Xie, Y; Zhang, X; Zong, C | 1 |
| Aidinis, V; Bouros, D; Kaffe, E; Karameris, A; Mouratis, MA; Oikonomou, N; Prestwich, GD; Tzouvelekis, A; Valavanis, C; Vilaras, G | 1 |
| Allard, J; Apparsundaram, S; Budd, DC; Chen, Y; Coyle, L; Deguzman, J; Fuentes, ME; Guo, L; Hamid, R; Kitson, C; Majmudar, R; Qian, Y; Ren, Y; Tang, X; Truitt, T | 1 |
| Tager, AM | 1 |
4 review(s) available for lysophosphatidic acid and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Cellular and Molecular Control of Lipid Metabolism in Idiopathic Pulmonary Fibrosis: Clinical Application of the Lysophosphatidic Acid Pathway.
Topics: Endothelial Cells; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lipid Metabolism; Lysophospholipids | 2023 |
Signalling by lysophosphatidate and its health implications.
Topics: Animals; Cardiovascular Diseases; Female; Humans; Idiopathic Pulmonary Fibrosis; Inflammation; Lysophospholipids; Neoplasms; Phosphatidate Phosphatase; Phosphoric Diester Hydrolases; Pregnancy; Pregnancy Complications; Receptors, G-Protein-Coupled; Signal Transduction; Wound Healing | 2020 |
Druggable Lysophospholipid Signaling Pathways.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Molecular Targeted Therapy; Receptors, Lysophosphatidic Acid; Scleroderma, Systemic; Signal Transduction | 2020 |
Autotaxin inhibitors: a patent review (2012-2016).
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Neoplasms; Patents as Topic; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2017 |
4 trial(s) available for lysophosphatidic acid and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA
Topics: Adult; Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Receptors, Lysophosphatidic Acid; Vital Capacity | 2021 |
Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosis.
Topics: Biomarkers; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids | 2023 |
Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Topics: Adult; Aged; Antibiotics, Antitubercular; Biomarkers, Pharmacological; Case-Control Studies; Dose-Response Relationship, Drug; Drug Interactions; Female; Healthy Volunteers; Humans; Idiopathic Pulmonary Fibrosis; Imidazoles; Lysophospholipids; Male; Middle Aged; Phosphoric Diester Hydrolases; Pyrimidines; Rifampin | 2019 |
Challenges in accurate quantitation of lysophosphatidic acids in human biofluids.
Topics: Bronchoalveolar Lavage Fluid; Chromatography, Liquid; Female; Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Male; Mass Spectrometry | 2014 |
9 other study(ies) available for lysophosphatidic acid and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Lysophosphatidic acid, ceramide 1-phosphate and sphingosine 1-phosphate in peripheral blood of patients with idiopathic pulmonary fibrosis.
Topics: Ceramides; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Sphingosine | 2022 |
Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Receptors, Lysophosphatidic Acid | 2023 |
CREB-dependent LPA-induced signaling initiates a pro-fibrotic feedback loop between small airway basal cells and fibroblasts.
Topics: Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Epithelial Cells; Fibroblasts; Gene Expression Regulation; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lysophospholipids; Nerve Tissue Proteins; RNA, Messenger; Signal Transduction | 2021 |
Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Topics: Animals; Benzoxazoles; Biphenyl Compounds; Bleomycin; Idiopathic Pulmonary Fibrosis; Isoxazoles; Kaplan-Meier Estimate; Lung; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Random Allocation | 2018 |
Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis.
Topics: Aged; Breath Tests; Female; Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Male | 2014 |
Transforming growth factor-β inhibits IQ motif containing guanosine triphosphatase activating protein 1 expression in lung fibroblasts via the nuclear factor-κB signaling pathway.
Topics: Animals; Bleomycin; Cell Differentiation; Fibroblasts; Gene Expression Regulation; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lysophospholipids; Mice; NF-kappa B; ras GTPase-Activating Proteins; Signal Transduction; Transforming Growth Factor beta | 2015 |
Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis.
Topics: Adult; Aged; Anilides; Animals; Bronchoalveolar Lavage Fluid; Female; Gene Expression; Gene Knockout Techniques; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lysophospholipids; Macrophages, Alveolar; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Organophosphonates; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Respiratory Mucosa | 2012 |
Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells.
Topics: Arteries; Calcium; DNA Primers; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lysophospholipids; Microcirculation; Microscopy, Fluorescence; Permeability; Polymerase Chain Reaction; Receptors, G-Protein-Coupled; Receptors, Lysophosphatidic Acid; RNA, Small Interfering; Time Factors | 2013 |
Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis.
Topics: Animals; Clinical Trials as Topic; Humans; Idiopathic Pulmonary Fibrosis; Lysophospholipids; Molecular Targeted Therapy; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Signal Transduction | 2012 |